- Home
- MRM vs SYBX Comparison
MRM vs SYBX Comparison
Compare MRM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | SYBX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 15.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRM | SYBX |
|---|---|---|
| Price | $2.07 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.2K | 78.8K |
| Earning Date | 05-22-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.02 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $0.90 |
| 52 Week High | $4.45 | $1.96 |
Technical Indicators
Market Signals| Indicator | MRM | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 42.29 |
| Support Level | $2.10 | $1.15 |
| Resistance Level | $2.28 | $1.22 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 16.72 | 62.50 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.